FR08C0001I2 - - Google Patents

Info

Publication number
FR08C0001I2
FR08C0001I2 FR08C0001C FR08C0001C FR08C0001I2 FR 08C0001 I2 FR08C0001 I2 FR 08C0001I2 FR 08C0001 C FR08C0001 C FR 08C0001C FR 08C0001 C FR08C0001 C FR 08C0001C FR 08C0001 I2 FR08C0001 I2 FR 08C0001I2
Authority
FR
France
Prior art keywords
formulation
deslorelin
mug
testosterone
cats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0001C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptech Animal Health Pty Ltd
Original Assignee
Peptech Animal Health Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech Animal Health Pty Ltd filed Critical Peptech Animal Health Pty Ltd
Publication of FR08C0001I1 publication Critical patent/FR08C0001I1/fr
Application granted granted Critical
Publication of FR08C0001I2 publication Critical patent/FR08C0001I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR08C0001C 1995-06-20 2008-01-10 Active FR08C0001I2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN3667A AUPN366795A0 (en) 1995-06-20 1995-06-20 Formulation for preventing reproductive function
PCT/AU1996/000370 WO1997000693A1 (en) 1995-06-20 1996-06-20 Novel formulation for peptide release

Publications (2)

Publication Number Publication Date
FR08C0001I1 FR08C0001I1 (es) 2008-03-21
FR08C0001I2 true FR08C0001I2 (es) 2009-11-20

Family

ID=3788008

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0001C Active FR08C0001I2 (es) 1995-06-20 2008-01-10

Country Status (17)

Country Link
US (2) US5925619A (es)
EP (1) EP0871467B1 (es)
JP (1) JP4016133B2 (es)
CN (1) CN1145496C (es)
AT (1) ATE223726T1 (es)
AU (2) AUPN366795A0 (es)
CA (1) CA2225796C (es)
DE (2) DE122008000004I2 (es)
DK (1) DK0871467T3 (es)
ES (1) ES2182983T3 (es)
FR (1) FR08C0001I2 (es)
HK (1) HK1014874A1 (es)
NL (1) NL300330I2 (es)
NZ (1) NZ309697A (es)
PT (1) PT871467E (es)
SI (1) SI0871467T1 (es)
WO (1) WO1997000693A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
DK1007080T3 (da) * 1996-08-30 2007-07-30 Peptech Ltd Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH
US8052982B2 (en) * 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US6211221B1 (en) * 1999-04-05 2001-04-03 Johnny W. Peterson Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
AU2004313245B2 (en) * 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
EP1835885A1 (en) * 2004-12-23 2007-09-26 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
RU2010114029A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Астрессин и бета-эндорфин для применения в качестве терапевтических средств
DE102008015104A1 (de) 2008-03-19 2009-09-24 Basf Coatings Ag Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563846B2 (es) * 1972-10-12 1981-01-27
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function

Also Published As

Publication number Publication date
FR08C0001I1 (es) 2008-03-21
NL300330I1 (nl) 2008-03-03
EP0871467B1 (en) 2002-09-11
CN1188414A (zh) 1998-07-22
CA2225796A1 (en) 1997-01-09
DE69623652T2 (de) 2003-05-28
EP0871467A1 (en) 1998-10-21
JP2001521482A (ja) 2001-11-06
PT871467E (pt) 2002-12-31
AUPN366795A0 (en) 1995-07-13
AU5992796A (en) 1997-01-22
US6211152B1 (en) 2001-04-03
DE122008000004I1 (de) 2008-04-17
SI0871467T1 (en) 2003-08-31
CN1145496C (zh) 2004-04-14
US5925619A (en) 1999-07-20
DE122008000004I2 (de) 2009-08-06
EP0871467A4 (en) 2000-07-05
ATE223726T1 (de) 2002-09-15
NL300330I2 (nl) 2008-04-01
DK0871467T3 (da) 2002-12-23
WO1997000693A1 (en) 1997-01-09
AU701837B2 (en) 1999-02-04
HK1014874A1 (en) 1999-10-08
ES2182983T3 (es) 2003-03-16
JP4016133B2 (ja) 2007-12-05
CA2225796C (en) 2011-09-20
NZ309697A (en) 1999-11-29
DE69623652D1 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
FR08C0001I2 (es)
AU4718496A (en) Use of aerogels in agriculture
AU560829B2 (en) Continuous release pharmaceutical compositions
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
PL313223A1 (en) Nigella sativa as a therapeutic agent
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
MY164077A (en) Compositions and uses of et743 for treating cancer
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
AU5673399A (en) Compositions and methods for treating intracellular infections
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
WO1994020115A3 (en) Hyaluronic acid used as a cancer treatment
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
OA09771A (en) Asphodelus composition for increasing white blood cell count.
BG51699A1 (en) Stimulating fertility agent
UA30723A (uk) Спосіб лікування аутоімунних захворювань
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
UA7163A (uk) Спосіб відновлення ушкоджених тканин людини чи тварини